To open the online version please click here.

Dear Sir or Madam,

We would like to draw your attention to the following press release of Imcyse S.A.:

Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder

  • Pfizer takes equity stake in Imcyse as part of the recently announced Rheumatoid Arthritis license agreement
  • Major existing shareholders participated in the round
  • Proceeds to advance Imcyse’s pipeline of first-in-class targeted disease modifying immunotherapeutics

Liège, Belgium, February 17, 2021 Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced that it has concluded a Series B extension financing round, raising EUR 21.3 million (USD 25.8 million). Participants of the new round included existing investors, Biogenosis, Epimede, LSP, Noshaq, Société Régionale d'Investissement de Wallonie (SRIW), Société Fédérale de Participations et d'Investissement (SFPI) and KU Leuven. Pfizer Inc. (NYSE: PFE) also participated as Imcyse’s newest investor taking an equity stake in the Company as part of the license agreement for Imcyse’s Rheumatoid Arthritis (RA) program based on the Company’s ImotopeTM technology announced on February 3, 2021.

Denis Bedoret, Imcyse CEO, commented: “Completing this financing round reinforces the strength of the Company allowing us to advance our programs to the next phase of development. Our aim is to be a major player in active specific immunotherapy. In this pursuit, we have taken our lead ImotopeTM candidate into phase 2 for Type 1 Diabetes and have four other programs running in Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Celiac Disease and Rheumatoid Arthritis. I would like to express our gratitude to our existing shareholders and to our new investor, Pfizer, for their support and confidence in our ImotopeTM platform.”

Proceeds from the latest financing round will be used to accelerate the advancement of several first-in-class targeted disease modifying immunotherapeutics, developing a robust and diverse clinical pipeline. In accordance with Imcyse’s corporate strategy, the Company remains open to new partnerships and investors to further support its development and expansion into the U.S.

ImotopeTM platform to prevent, stop and potentially cure autoimmune diseases
The Imcyse ImotopeTM platform represents a next generation and potentially curative approach to severe autoimmune diseases for which there is no satisfactory therapy. ImotopesTM induce cytolytic T cells, which specifically eliminate the aberrant disease pathway while leaving the rest of the immune system unaffected. In addition to the Type 1 Diabetes program, its Multiple Sclerosis candidate is expected to commence clinical trials by 2022. In RA, Pfizer and Imcyse will collaborate to develop existing lead candidates and further optimize potential molecules. After a candidate is selected, Pfizer will lead clinical development and commercialisation activities.

###

ABOUT IMCYSE

Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases. The company’s unique technology platform allows it to specifically target immune cells involved in the destruction of the diseased organ. Disease specific Imotopes™, which are modified peptides, generate cytolytic CD4+ T-cells, that eliminate antigen-presenting cells and autoantigen specific lymphocytes. The Imotope™ effect, sustained over time, helps to prevent and treat diseases with no current curative alternative and to potentially cure patients without causing generalized immune suppression. The company has established proof of concept in several indications and has started a Phase 2 clinical program in type 1 diabetes with promising results already seen during the first Phase 1 trial. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases. Founded as a spin-off of the Catholic University of Leuven Imcyse subsequently relocated to Liège, Belgium.

www.imcyse.com

CONTACT:

Imcyse S.A.
Denis Bedoret
Chief Executive Officer                        
Mail: contact@imcyse.com  

FOR MEDIA INQUIRES: 

MC Services AG
Anne Hennecke / Brittney Sojeva
Mail: imcyse@mc-services.eu
Tel.: +49 (0) 211-529-252-14

 

- End of press release 

Should you have any questions or would like to receive further information, please do not hesitate to contact us.

Best regards,

Brittney Sojeva

MC Services AG
phone: +49 211 529252 14
email: brittney.sojeva@mc-services.eu  

www.mc-services.eu
MC Services AG

Handelsregister/Commercial Register: Amtsgericht Augsburg HRB 2117
Vorstand/Management Board: Raimund Gabriel, Anne Hennecke
Aufsichtsrat/Supervisory Board: Johannes Gabriel (Vorsitzender/Chairman)
This message may contain confidential and/or privileged information. If you are not the addressee or authorized to receive this for the addressee, you must not use, copy, disclose or take any action based on this message or any information herein. If you have received this message in error, please advise the sender immediately by reply e-mail and delete this message. Thank you for your cooperation.
If you wish to be removed from the Imcyse distribution list, please click here.
In accordance with the new EU General Data Protection Regulation (GDPR), we ask for your consent to continue sending you press releases and other information. If we do not receive any feedback from you, we will continue to send you press releases in the future. You can revoke your consent to receive information and to store data at any time and without giving reasons by e-mail to contact@mc-services.eu.